$SLDB News

Solid Biosciences Announces European Commission Orphan Designation for SGT-212 and Continued Progress in the FALCON Trial in Friedreich’s Ataxia

Solid Biosciences Says European Commission Grants Orphan Designation To SGT-212 For Treatment Of Friedreich’s Ataxia

Solid Biosciences to Present Research Across Gene Therapy Development, Delivery and Manufacturing at ESGCT 2026

UBS Initiates Coverage On Solid Biosciences with Buy Rating, Announces Price Target of $20

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Solid Biosciences: A Funded Challenge To Duchenne Gene Therapy's Limitations

RBC Capital Initiates Coverage On Solid Biosciences with Outperform Rating, Announces Price Target of $18

HC Wainwright & Co. Reiterates Buy on Solid Biosciences, Maintains $25 Price Target

Solid Biosciences Inc. (SLDB) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Solid Biosciences to Participate at Upcoming Investor Conferences

Cantor Fitzgerald Maintains Overweight on Solid Biosciences, Raises Price Target to $26

Truist Securities Maintains Buy on Solid Biosciences, Raises Price Target to $20

Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates

Solid Biosciences Q2 EPS $(0.38) Beats $(0.46) Estimate

Solid Biosciences Files Prospectus To Offer Up To $200M In Common Stock

Solid Biosciences: The Bull Case Is No Longer Just Duchenne

Does Solid Biosciences' (SLDB) Russell Growth Index Debut Reveal a Shift in Its Investor Base?

Solid Biosciences Inc. (SLDB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

HC Wainwright & Co. Maintains Buy on Solid Biosciences, Raises Price Target to $25

Solid Biosciences and NanoMosaic Announce Co-Marketing Agreement to Advance Gene Therapy Delivery and Analytics